TABLE 1.
Demographic and clinical characteristics of the study population
| Characteristics (total n = 59) | N (%); Mean ± SD |
|---|---|
| Gender | |
| Male | 34 (57.62) |
| Female | 25 (42.38) |
| Age (years) | 53.54 ± 12.99 |
| BMI (kg/m2) | 27.49 ± 5.35 |
| Arthropathy | |
| No | 52 (81.14) |
| Yes | 7 (11.86) |
| Familiarity | |
| No | 38 (64.41) |
| Yes | 21 (35.59) |
| Age of onset (years old) | 31.27 ± 15.65 |
| Treatment duration (mo) with tildrakizumab | 12.96 ± 3.60 |
| Previous treatment | |
| Phototherapy | 11 (18.64) |
| CyA | 24 (40.67) |
| Methotrexate | 34 (57.62) |
| Acitretin | 8 (13.56) |
| Apremilast | 13 (22.03) |
| Infliximab | 2 (3.38) |
| Etanercept | 7 (11.86) |
| Adalimumab | 11 (18.64) |
| Golimumab | 2 (3.38) |
| Certolizumab | 1 (1.69) |
| Ustekinumab | 6 (10.17) |
| Secukinumab | 9 (15.25) |
| Ixekizumab | 4 (6.78) |
| Guselkumab | 1 (1.69) |
| Brodalumab | 2 (3.38) |
| Last biological treatment | |
| Naïve | 35 (59.32) |
| Anti‐TNFα | 8 (13.56) |
| Anti‐IL17 | 10 (16.94) |
| Anti‐IL23 or Anti‐IL12/23 | 4 (6.78) |
| Comorbidities | |
| Hypertension | 20 (33.90) |
| Diabetes | 12 (20.33) |
| Dyslipidemia | 30 (50.84) |
| Others | 11 (18.64) |
Abbreviations: BMI, body mass index; CyA, cyclosporine A; SD, standard deviation.